Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 6.7% - Should You Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) shares shot up 6.7% on Wednesday . The company traded as high as $0.55 and last traded at $0.49. 59,902,238 shares changed hands during mid-day trading, a decline of 42% from the average session volume of 103,490,164 shares. The stock had previously closed at $0.46.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a report on Saturday, January 25th. They set a "hold" rating on the stock.

Tonix Pharmaceuticals Stock Performance

The firm's 50-day simple moving average is $0.30 and its two-hundred day simple moving average is $0.28. The stock has a market capitalization of $80.01 million, a PE ratio of -0.01 and a beta of 2.02. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. On average, equities research analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC bought a new position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 218,003 shares of the company's stock, valued at approximately $72,000. PFG Investments LLC owned approximately 0.12% of Tonix Pharmaceuticals as of its most recent SEC filing. 82.26% of the stock is currently owned by hedge funds and other institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.